Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Ocuphire Pharma Inc (OCUP)
Ocuphire Pharma Inc (OCUP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Ocuphire Pharma Inc 37000 GRAND RIVER AVE. SUITE 120 FARMINGTON HILLS MI 48335 USA

www.ocuphire.com P: 248-957-9024

Description:

Ocuphire Pharma Inc. is a clinical-stage ophthalmic biopharmaceutical company. It is focused on developing and commercializing therapies for the treatment of several eye disorders. The company's product pipeline includes Nyxol Eye Drops(R) and APX3330. Ocuphire Pharma Inc., formerly known as Rexahn Pharmaceuticals Inc., is based in FARMINGTON HILLS, Mich.

Key Statistics

Overview:

Market Capitalization, $K 59,764
Enterprise Value, $K 17,134
Shares Outstanding, K 22,638
Annual Sales, $ 39,850 K
Annual Net Income, $ 17,890 K
Last Quarter Sales, $ 11,940 K
Last Quarter Net Income, $ 5,560 K
EBIT, $ -10,770 K
EBITDA, $ -10,770 K
60-Month Beta 0.34
% of Insider Shareholders 8.70%
% of Institutional Shareholders 17.37%
Float, K 20,668
% Float 91.30%
Short Volume Ratio 0.44

Growth:

1-Year Return -24.14%
3-Year Return -71.79%
5-Year Return -90.32%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 103.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.25 on 11/13/23
Latest Earnings Date 04/04/24
Earnings Per Share ttm 1.31
EPS Growth vs. Prev Qtr 204.17%
EPS Growth vs. Prev Year 213.64%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 11/06/20

OCUP Ratios

Ratio
Price/Earnings ttm 1.93
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % 65.54%
Return-on-Assets % 59.88%
Profit Margin % 44.89%
Debt/Equity 0.00
Price/Sales 1.00
Price/Cash Flow 2.91
Price/Book 1.04
Book Value/Share 2.39
Interest Coverage 1,821.00
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar